Abstract
The abnormal glycosylation and loss of extracellular matrix receptor function of the protein dystroglycan (DG) lead to the development of muscular dystrophy and cardiomyopathy. Dystroglycan is an important receptor for extracellular matrix proteins, such as laminin, in the basement membrane surrounding muscle. Largemyd mice have a null mutation in a gene encoding the glycosyltransferase LARGE that results in abnormal glycosylation of α-DG and phenotypes similar to those in human α-DG glycosylation-deficient muscular dystrophy. Here, we show that Largemyd hearts with the loss of DG extracellular matrix receptor function display a cardiomyopathy characterized by myocyte damage in patches of cells positive for membrane impermeant dyes. To examine the cellular mechanisms, we show that isolated adult cardiac myocytes from Largemyd mice retain normal laminin-dependent cell adhesion, cell surface laminin deposition and basement membrane assembly. However, although isolated adult cardiac myocytes with the loss of α-DG glycosylation adhere normally to laminin substrates both passively and in the presence of mechanical activity, Largemyd myocytes rapidly take up membrane impermeant dye following cyclical cell stretching. Therefore, while other cell surface laminin receptors are likely responsible for myocardial cell adhesion to the basement membrane, DG has a unique function of stabilizing the cardiac myocyte plasma membrane during repetitive mechanical activity by tightly binding the transmembrane dystrophin–glycoprotein complex to the extracellular matrix. This function of DG to stabilize the myocyte membrane during normal physiologic cell length changes is likely critical for the prevention of the myocardial damage and subsequent remodeling observed in α-DG glycosylation-deficient muscular dystrophies.
INTRODUCTION
Muscular dystrophies are a group of clinically and genetically heterogeneous diseases unified by the presence of progressive skeletal muscle weakness and wasting. Many patients with muscular dystrophies, particularly with those associated with alterations in the dystrophin–glycoprotein complex (DGC), develop cardiomyopathy (1–4). Abnormal glycosylation of the protein α-dystroglycan (α-DG) within the DGC leads to a spectrum of muscular dystrophies varying from severe congenital forms such as Fukuyama congenital muscular dystrophy (FCMD), Walker–Warburg syndrome (WWS), muscle–eye–brain disease (MEB) and congenital muscular dystrophy 1D (MDC 1D) to milder forms such as limb girdle muscular dystrophies (LGMD 2I, 2K, 2M, 2N, 2O) (5,6). The congenital forms of these muscular dystrophies, in addition to skeletal muscle and heart involvement, are characterized by varying degrees of developmental brain and eye abnormalities and peripheral neuropathy. The genetic defects underlying α-DG glycosylation-deficient muscular dystrophies reside in several genes encoding for glycosyltransferases involved in O-glycosylation of α-DG. The glycosylation steps and the precise composition of sugar residues on α-DG are not fully elucidated, but LARGE seems to be essential for sugars required for DG function (7,8). LARGE is a glycosyltransferase with two predicted catalytic domains and is highly expressed in skeletal muscle, heart and brain (9,10). Human and mouse LARGE have 98% identity in the amino acid sequence, and α-DG is the only known LARGE substrate that has been identified (9). Although the enzymatic activity of LARGE is still unclear, overexpression of LARGE in fibroblasts and myoblasts from human patients rescues α-DG glycosylation and laminin-binding activity (7). In humans, mutations in the LARGE gene cause congenital muscular dystrophy 1D (11). The Largemyd mouse has a naturally occurring null mutation in the LARGE gene that results in skeletal muscle, cardiac and brain phenotypes similar to that observed in humans (5,9,12), and therefore can be used as a model to study pathogenesis of α-DG glycosylation-deficient muscular dystrophies resulting from the loss of DG function. While mutations in DG itself appear to be quite rare, the very first case of a genetic defect in the α-DG protein associated with human LGMD and cognitive impairment was published recently (13). Interestingly, this missense mutation also results in abnormal glycosylation of α-DG and loss of its laminin-binding ability, suggesting that the functional consequences of this particular mutation will be similar to the effects of genetic defects in the enzymes responsible for α-DG glycosylation.
Dystroglycan (DG) is the central component of the DGC, located in the plasma membrane of the skeletal muscle fibers and cardiac muscle cells. α-DG, an extracellular subunit of DG, and β-DG, an integral membrane DG subunit, play a key role in the DGC by linking the extracellular matrix to the cell cytoskeleton (14). DG serves as a receptor for a variety of extracellular matrix proteins containing laminin-G domains, such as laminin (15), neurexin (16) and agrin (17). α-DG is heavily glycosylated, and proper glycosylation is required for DG's function as an extracellular matrix receptor (14,16). Largemyd hearts show loss of α-DG glycosylation and consequent loss of high-affinity laminin-binding activity (18).
In muscular dystrophies due to genetic defects in DGC proteins, there is a destabilization and reduction/loss of the entire complex, suggesting that the loss of proteins constituting the DGC may also impact the function of DG within the complex (12,15,19,20). Sensitivity to contraction-induced damage is thought to be one of the mechanisms causing skeletal muscle degeneration in a number of muscular dystrophies associated with alterations in DGC function. However, independent of the DGC, α-DG has been shown to play a role in cell adhesion in certain type of cells (21). For instance, aberrant glycosylation of α-DG and impaired cell adhesion are associated with a highly invasive cellular phenotype in epithelia-derived cancers (22,23). α-DG in many non-muscle tissues also anchors laminin on the cell surface to facilitate formation of laminin polymers and basement membrane assembly (24–26). A body-wide ablation of DG results in embryonic lethality due to a failure to form Reichert's membrane, one of the earliest basement membranes in rodent embryos (27).
Dilated cardiomyopathy and measureable left ventricular dysfunction are a frequent feature of α-DG-deficient muscular dystrophies (4,28–33). The majority of cardiomyopathy cases are reported in LGMD 2I and FCMD and, in most of the cases, patients develop cardiomyopathy in later stages of disease. One recent study reported that 60% of patients with LGMD 2I enrolled had reduced left ventricular ejection fraction (33). In FCMD, a significant correlation between left ventricular systolic function and age was reported, and systolic function was reduced in most patients over 15 years old (4). A severe and early onset cardiomyopathy can also be an isolated presentation of muscular dystrophy, as patients with FKRP and fukutin mutations have been reported to present with congestive heart failure in the presence of very minimal skeletal muscle weakness or asymptomatic hyperCKemia (34,35). One of those patients died from heart failure, and two underwent heart transplantation in the first and second decade of life. No correlation has been shown to exist between the severity of skeletal muscle disease and cardiomyopathy (28,30,33). To our knowledge, there have been few if any reports of cardiac involvement in WWS or MEB, but the short lifespan of these patients may preclude the development of significant heart disease.
The exact mechanism for the heart disease in α-DG glycosylation-deficient muscular dystrophy is largely unknown. Targeted deletion of DG in cardiac muscle cells is sufficient to cause a dilated cardiomyopathic phenotype characterized by focal patches of damaged cardiac myocytes that take up Evan's blue dye prior to onset of pathological remodeling (18). Despite evidence of a potential cardiac muscle cell intrinsic phenotype of loss of DG matrix receptor function in vivo, it still is not clear how and why cardiac tissue is more sensitive to damage and why the resultant phenotype is focal in nature. The observed phenotypes in vivo could be the result of the direct effects of loss of α-DG glycosylation, or a combination of secondary factors caused by the onset of cardiac disease. Here we show that the loss of α-DG glycosylation in Largemyd hearts results in patches of damaged cardiac myocytes. To determine the cellular mechanism for why abnormal α-DG glycosylation leads to membrane damage, we show that, despite little to no effects on cellular adhesion or matrix assembly, loss of α-DG extracellular matrix receptor function renders isolated Largemyd cardiac myocytes sensitive to mechanical stretch-induced membrane damage. Therefore, we provide direct evidence for membrane instability caused by loss of DG function as an extracellular matrix receptor in cardiac myocytes as a primary mechanism of focal cardiac myocyte damage and fibrotic remodeling in α-DG glycosylation-deficient muscular dystrophy.
RESULTS
Loss of DG glycosylation results in myocardial damage focal in nature
Since hearts of patients and mice with abnormal α-DG glycosylation develop focal fibrosis (4,18), and the DGC is thought to maintain membrane stability, we hypothesized that focal cardiac necrosis as a result of ongoing cell membrane damage is a basis for fibrotic remodeling in α-DG glycosylation-deficient hearts. To test this hypothesis, we examined hearts from wild-type (WT) and Largemyd mice for intracellular uptake of IgG, which is normally excluded from the cell if plasma membrane is intact. Recent work in our laboratory (18) showed that immunoglobulin uptake is identical to marking cells by Evan's blue dye uptake without requiring dye injection (Supplementary Material, Fig. S1). Similarly, an earlier study showed an overlap of IgG and Evan's blue dye positive areas in dystrophic skeletal muscle (36). Analysis of serial sections from WT and Largemyd animals revealed a specific pattern of IgG uptake in which cells taking up IgG are clustered together forming an IgG positive patch (Fig. 1A). In each group, we quantified IgG positive areas and number of individual cells taking up IgG to find that the number of IgG-positive cell clusters was significantly greater in Largemyd hearts compared with WT hearts (Fig. 1B, left panel). We found only three one- and two-cell positive areas in 16 sections from four WT hearts, whereas in Largemyd mice there was an increase in number of observed patches as well as a manifestation of patches containing up to 30 IgG-positive cells in cross-section (Fig. 1B, right panel). Interestingly, patches often contained cells in the same orientation, i.e. same mechanical axis, suggesting that distribution of the force or stretch along this axis might play a role in how patches form. Taken together, these results show that Largemyd mice have focal areas of myocardial cell damage where clusters of neighboring cardiac myocytes appear to be preferentially affected.
Figure 1.
Loss of DG glycosylation results in focal myocardial damage. (A) Representative images from sedentary WT and Largemyd mice showing intracellular uptake of IgG (green). A pan-laminin antibody was used to mark cell boundaries to facilitate scoring of individual myocytes. Damaged cardiac myocytes were clustered in patches of variable size and arranged in same orientation. (B) Quantification of patches. The number of IgG-positive patches was significantly greater in Largemyd hearts compared with WT animals (left panel). There was an increase in number of individual cardiac myocytes constituting a patch in Largemyd animals (right panel), although it did not reach a significance level due to a high variation. Data are mean ± SD, n = 4 for each group, age WT 36.8 ± 4.6 and MYD 36.5 ± 4.4, four serial sections per animal were analyzed. Abbreviations used throughout all figures: WT, wild-type; MYD, Largemyd.
Largemyd cardiac myocytes retain their adhesive properties
To investigate the potential direct cellular mechanisms underlying clustered cell damage in myocardium of Largemyd mice, we enzymatically isolated cardiac myocytes from WT and Largemyd mice. Viability of Largemyd cardiac myocytes following the enzymatic isolation was comparable with that of WT cells, and myocytes from Largemyd showed rod-shaped morphology similar to myocytes from WT mice (Fig. 2A and C). Cardiac myocytes from some Largemyd mice tend to be thinner and smaller in size than WT cells. Although this might be an intristic characteristic of cardiac myocytes with abnormally glycosylated α-DG, Largemyd animals are generally smaller than their WT littermates and thus have proportionally smaller hearts (Supplementary Material, Fig. S2). Biochemical analysis of isolated cardiac myocytes showed that the peripheral membrane α-DG recognized by the IIH6 antibody against fully glycosylated, laminin-binding form of α-DG was present on the cell surface of WT cells (as opposed to secreted in the culture media) (Fig. 2B). Largemyd cardiac myocytes showed complete loss of α-DG detected by the IIH6 antibody due to the loss of glycosylation, but retained DG expression as detected by a β-DG antibody (Fig. 2B).
Figure 2.
Cardiac myocytes isolated from adult Largemyd mice show normal viability and loss of α-DG glycosylation. (A) The viability of mutant cardiac myocytes defined as a percentage of rod-shaped to total number of cells was not significantly different from that of WT heart cells. Data are mean ± SEM. (B) Largemyd myocytes showed complete loss of α-DG detected by the IIH6 antibody due to the loss of glycosylation (top panel), but retained DG expression as detected by a β-DG antibody (middle panel). A portion of the Ponceau S-stained blot is to show equal loading (bottom panel). (C) Cardiac myocytes from Largemyd showed rod-shaped morphology similar to myocytes from WT mice. Abbreviations: glyc α-DG, glycosylated α-DG.
α-DG as an extracellular matrix receptor has been shown to play a role in cell adhesion in certain type of cells (21–23); however, data on the role of DG in cardiac myocyte cell adhesion are lacking. We hypothesized that possibly abnormal adhesion underlies myocardial damage observed in Largemyd hearts. We developed assay conditions to quantify the laminin-dependent adhesion of cardiac myocytes to matrix-coated surfaces. Freshly isolated adult mouse cardiac myocytes show laminin dose-dependent adhesion to glass cover slips in the absence of fetal bovine serum (Fig. 3A), which is abolished by treating cells with ethylenediaminetetraacetic acid (EDTA) and trypsin but not with arginine-glycine-aspartic acid (RGD) peptide (Supplementary Material, Figs S3 and S4). Using this assay, we compared laminin-dependent adhesion properties of cardiac cells isolated from WT and Largemyd hearts, and found that number of Largemyd cells adherent to laminin-coated glass cover slips did not differ from that of WT cells (Fig. 3B).
Figure 3.
Loss of α-DG glycosylation is not detrimental for adhesion of cardiac myocytes to laminin substrata. (A) Freshly isolated adult mouse cardiac myocytes show laminin (LM) dose-dependent adhesion to glass cover slips in the absence of fetal bovine serum. Data are mean ± SEM; n = 3 for each group; *P < 0.05 versus all groups with 5% serum and the 50 µg/ml LM group with no serum. (B) Abnormal glycosylation of α-DG does not interfere with cardiac myocytes adhesion to laminin substratum. Data are mean ± SEM; n = 6 for each group; *P < 0.05 versus 50 µg/ml laminin groups.
Laminin deposition on the cell surface is independent of α-DG glycosylation
DG has been shown to be involved in the assembly of basement membranes by nucleating and depositing laminin on cell surface (24–27,37). To test the hypothesis that DG function as a laminin receptor is essential for laminin deposition and basement membrane assembly, we looked at cell surface and total laminin expression on adult mouse cardiac myocytes. During isolation of single cardiac myocytes, a considerable amount of basement membrane remains tightly associated with myocytes on the cell surface as shown by immunostaining for surface laminin (Fig. 4A). In addition, IIH6-reactive α-DG is present on the cell surface of WT myocytes. While in myocytes from Largemyd hearts, IIH6-reactive laminin-binding glycoform of α-DG was undetectable, no difference in laminin staining on the surface of freshly isolated Largemyd and WT cardiac myocytes was observed, suggesting the basement membrane remains tightly associated with the cardiac myocyte surface membrane even under fairly harsh conditions of cell isolation (Fig. 4A). Western blotting of cell pellets prepared from freshly isolated cardiac myocytes showed that the amounts of laminin associated with the Largemyd cells are similar to WT cells (Fig. 4B). Immunostaining of heart sections from Largemyd and WT mice with a pan-laminin as well as laminin α2 chain antibody (Fig. 4C) showed similar levels of laminin deposition around mutant and WT cardiac myocytes with both antibodies. In order to determine whether the loss of α-DG glycosylation and function caused upregulation of integrins in cardiac myocytes to compensate for loss of DG function as matrix receptor, the expression of α7 and β1 integrin in the Largemyd heart was examined. Expression of integrin α7 and β1, the major integrin subunits in the heart, was unchanged (Fig. 4D).
Figure 4.
Laminin deposition on the cell surface is independent of α-DG glycosylation. (A) Largemyd cardiac myocytes show loss of staining with IIH6 antibody against glycosylated epitope of α-DG, but show the WT level of immunofluorescence when labeled with a pan-laminin antibody. Scale bar, 50 μm. (B) Western blot (WB) of freshly isolated cells showed that the amount of total laminin associated with the Largemyd cardiac myocytes is similar to that of WT cells (top panel). The bottom panel is a portion of the Ponceau S-stained blot to show loading. (C) Mutant hearts showed WT levels of laminin deposition at plasma membrane as assessed with a pan-laminin and laminin α2 chain (major cardiac α chain) antibodies. Scale bar, 100 µm. (D) Membrane expression of integrin α7 and β1, major integrin subunits in the heart, was unchanged as showed by western blotting of the microsome fraction of tissue homogenates.
Cardiac myocytes with abnormal α-DG glycosylation are sensitive to mechanical stretch
DG is a member of the DGC complex, which has been implicated in stabilizing muscle cells against contraction-induced damage in skeletal muscle (38). Although patients with α-DG-deficient muscular dystrophy and Largemyd mice show marked muscular dystrophy phenotype and signs of cardiomyopathy, it is still not fully understood whether the observed cell degeneration is indeed due to direct membrane instability. We developed a cell stretch assay for adult cardiac myocytes that mechanically strains cells in the presence of laminin-dependent adhesion to surface substrata. Cardiac myocytes were plated on silastic membranes, and the attachment of myocytes to the silastic membrane was dependent on precoating the membranes with 50 μg/ml of laminin (Fig. 5A). Following myocyte attachment, cardiac myocytes were subjected to cyclic stretch by application of vacuum pressure to the bottom of the dish resulting in 20% stretch of the silastic membrane. The stretch was performed in the presence of propidium iodide, a membrane-impermeable fluorescent dye (39), with the rationale that this dye would permanently mark nuclei of cells that became permeant to the dye, and would not be easily washed out if cells failed to reseal during the assay because of its tight association with DNA. Myocytes were scored for their rod-shaped morphology and uptake of propidium iodide. Following this assay, we commonly observed both rod-shaped and round cells positive for propidium iodide (Fig. 5B). Presence of rod-shaped cardiac myocytes positive for propidium iodide indicates that membrane damage most likely was repaired. Observation of round cells positive for the dye is likely indicative of plasma membrane damage resulting in cell contracture due to influx of calcium from the extracellular media. Quantification of Largemyd cardiac myocytes subjected to stretch showed a significantly greater number of dye-positive myocytes than of Largemyd mice on silastic membranes not subjected to stretch and both stretched and non-stretched control myocytes (Fig. 6). The number of round cells combined with positive rods was also significantly greater in stretched mutant cardiac myocytes than in non-stretched Largemyd myocytes, indicating some cells underwent permanent cell contracture. In contrast, stretching of parallel cultures of control myocytes subjected to stretch at the same time showed no significant increase in the number of propidium iodide-positive cardiac myocytes or an increase in the number of dye-positive round myocytes. The other interesting finding is that while Largemyd cardiac myocytes showed significant sarcolemma instability in response to stretch, there was no significant effect of the mutation on the total number of cells that remain attached to the silastic membranes (Fig. 6). Thus, in agreement with our data in Figure 3, in myocytes with the loss of DG extracellular ligand receptor function, no significant difference in adhesion can be revealed even when the attachment to matrix is strained mechanically. However, when stretch is applied, Largemyd myocytes show significantly elevated sarcolemma instability, often resulting in cell contracture.
Figure 5.
Stretch assay to reveal membrane instability. (A) Cardiac myocytes attach to silastic membranes in a laminin-dependent fashion. No attachment is observed on non-coated membranes. (B) Representative images of propidium iodide exclusion tested in Largemyd cardiac myocytes subjected to stretch. When cell membrane integrity gets compromised propidium iodide, gains access to the nucleus, where it complexes with DNA and renders the nucleus highly immunofluorescent. In our experiments, propidium iodide was added to wells prior to stretch and washed out after stretch. Number of rod-shaped and round cells with bright red fluorescence was quantified. Images have same exposure time. Scale bar, 100 μm.
Figure 6.
Loss of α-DG function renders cardiac myocytes sensitive to mechanical stretch-induced membrane damage. (A) The number of cardiac myocytes, which took up propidium iodide, was significantly greater in Largemyd stretch group, indicating membrane instability. (B) Similarly, an overall number of propidium iodide-positive rods and round-shaped cells were significantly greater in Largemyd cells subjected to stretch, suggesting reduced survival in response to stretch. (C) Stretch did not cause Largemyd cardiac myocytes to detach as the total number of cells attached to silastic membranes was comparable before and after mechanical stretch. Values are means ± SEM of three independent experiments; in each experiment, five to six random fields were counted; *P < 0.05 versus all other groups in (B) and (C). PI, propidium iodide.
DISCUSSION
In the present study, we show that the loss of α-DG glycosylation and loss of its extracellular matrix-binding activity in Largemyd hearts cause a cardiomyopathy characterized by focal cell damage and uptake of extracellular IgG, which is normally excluded from cells. The fate of these patches of damaged myocytes remains to be investigated. Although there is a possibility for active membrane repair, it is likely that at least some of the patches of cell damage become sites of replacement fibrosis. This might explain the focal nature of myocardial fibrosis observed in patients with α-DG glycosylation-deficient muscular dystrophy (4) and Largemyd mice (18). Given the relatively slow progression of cardiac disease in patients and mice, the focal loss of functional myocardium and fibrotic remodeling appears to be a cumulative process ultimately resulting in cardiac dysfunction.
Although the observation of uptake of IgG suggests myocardial cell damage occurs in vivo, the cellular mechanisms responsible for cellular damage were not clear. DG as a laminin receptor has been shown to be important for cell adhesion in other cell types (21–23). Cell adhesion has been also shown to be crucial for survival of cardiac myocytes in culture (40). However, we show here that the loss of α-DG glycosylation in Largemyd cardiac myocytes does not have any effect on overall cell adhesion properties, suggesting that abnormal cell adhesion is not a mechanism for patch formation. Abolishment of cardiac myocyte adhesion to laminin by trypsin and EDTA suggests that the cell adhesion is a protein-mediated Ca2+-dependent process. Integrins are alternative laminin-binding receptors involved in cell adhesion and cell to extracellular matrix linkage (41,42). Transgenic expression of striated muscle-specific integrin isoforms reduces dystrophy in mice (43). However, the lack of effect of loss of DG function on cell adhesion is not likely explained by compensatory upregulation of β1 containing integrins. There was no observable effect of RGD peptide on cardiac myocyte adhesion to laminin, at concentrations reported to inhibit cell adhesion of COS-7 cells to fibronectin (44). Furthermore, the expression of heart-specific integrin isoforms was unchanged in Largemyd mice. Therefore, normal levels of laminin-binding integrins or alternative laminin receptors are likely sufficient for cell adhesion and basement membrane assembly in cardiac myocytes, and loss of α-DG glycosylation is dispensable for these functions.
Cardiac muscle cells are tightly surrounded by basement membrane, a specialized form of extracellular matrix that has a very complex organization allowing it to be flexible and strong (41,45). Previous studies suggested that DG is required for basement membrane formation (26,27,37). A body-wide deletion of DG in a mouse leads to a failure to form Reichert's basement membrane (27). α-DG regulates laminin expression and nucleates laminin on the cell surface to facilitate basement membrane assembly, at least in ES cells (26,37). Skeletal muscle of patients with α-DG glycosylation-deficient muscular dystrophy shows slightly reduced amounts of laminin α2 chain, the major laminin α chain in striated muscle (28,46). In the present study, we did not observe any effects of loss of α-DG glycosylation on laminin deposition on the surface of cardiac myocytes from Largemyd hearts, suggesting that basement membrane formation in the heart is not affected by the loss of α-DG laminin-binding activity and that cell damage in vivo is not likely due to abnormal basement membrane assembly.
In striated muscle, DG and the DGC are hypothesized to anchor the sarcolemma to the basement membrane at costameres (47,48). Costameres and the DGC are also believed to be sites of lateral transmission of force from sarcomeres to the matrix (48,49). An earlier study reported that Largemyd mice show slightly reduced expression of dystrophin, β-DG and γ-sarcoglycan in the heart but not in the skeletal muscle (12). Although the reason for such tissue-dependent differences is unknown, the reduction in the expression of these proteins might alter stoichiometry of the DGC and along with the loss of α-DG glycosylation contribute to the observed phenotypes. However, skeletal muscle of Largemyd mice with preserved expression of the DGC proteins shows more severe phenotype than cardiac muscle. Sensitivity to contraction-induced plasma membrane damage is thought to be one of the mechanisms causing skeletal muscle degeneration in a number of muscular dystrophies associated with alterations in DGC function. The evidence supporting the membrane instability hypothesis comes from previous studies showing uptake of Evan's blue dye and leakage of muscle enzymes by dystrophic skeletal muscle (38,50). Leaky membranes may lead to influx of calcium ions and activation of calcium-activated proteolysis of sarcomeric and cytoskeletal proteins that perhaps contribute additionally to muscle instability and muscle dysfunction (51,52). Relative to skeletal muscle, considerably less data are available on the dystrophic heart disease. Heart sections of dystrophic animals show areas of focal myocardial necrosis and dye uptake (12,53). Cardiac myocytes from dystrophin-deficient mdx mice show abnormal calcium influx in response to stretch (54). Mice with cardiac-specific deletion of DG develop focal areas of myocardial damage positive for Evan's blue dye (18). In the present study, we observed similar patches of myocardial damage in Largemyd mice deficient in α-DG glycosylation and extracellular ligand receptor function. Importantly, we now show that adult cardiac myocytes isolated from these mice show signs of membrane fragility in response to mechanical stretching, demonstrating direct evidence for the membrane instability hypothesis at the cellular level as a mechanism for patch formation. What is remarkable about this effect on membrane stability is that it occurs due to the loss of function of a single laminin receptor on the cell surface and in the presence of normal laminin-mediated cell adhesion. Therefore, α-DG appears to have a direct function in stabilizing the sarcolemma over the normal physiological range of cardiac myocyte mechanical activity by tightly binding the transmembrane DGC and likely the intracellular costamere to the extracellular matrix. The anchorage of the costamere to the matrix may confer membrane stability by distributing the membrane deformation uniformly over the cell surface proportional to the underlying sarcomere length changes in response to stretch. A remaining question is how this membrane instability at the single cell level leads to a cascade of events that cause the focal patches of myocardial damage. One possibility is that the spontaneous damage of a single myocyte results in greater load or mechanical activity on neighboring myocytes. Because cardiac myocytes with the loss of DG function are also more sensitive to mechanical stretching, those neighboring cells experiencing greater mechanical load are more likely to experience subsequent membrane damage.
In vivo, the secondary consequences following cardiac muscle damage are certainly complex but also likely significant to the progressive worsening of cardiac disease with age in dystrophic patients and in mouse models. The initial injuries to myocardium may trigger local inflammation at the site of the injury and surrounding tissue and could contribute to the expansion of patches of cell damage. Infiltration by macrophages and cytotoxic T-lymphocytes has been proposed to contribute to myofiber injury in dystrophin-deficient skeletal muscle (51,55). The pathological hallmark of dystrophic cardiac muscle of older patients and mouse models appears to be focal myocardial fibrosis. It seems likely that local inflammation and the release of cytokines such as transforming growth factor beta (TGF-beta) may contribute to the focal activation of fibroblasts and development of tissue fibrosis in dystrophic cardiac muscle. Indeed, treatment of dystrophin-deficient mice with losartan, which indirectly antagonizes TGF-beta function, appears to decrease fibrosis and improve cardiac function (56), although the mechanism of benefit of losartan and mechanisms of fibrosis in dystrophic myocardium remain to be investigated.
Our findings indicate that cardiac myocytes void of the glycosylated α-DG epitope are more sensitive to stretch-induced membrane damage at levels of stretch that reflect the length changes that occur during normal myocardial function. Normal deposition of laminin on the surface of myocytes and retained attachment of α-DG glycosylation-deficient myocytes to laminin during stretching indicates that the stretch-induced damage in the plasma membrane is not due to the weaker attachment of the cells to underlying matrix, but rather due to primary instability of the plasma membrane. Therefore, anchorage of the DGC to the basement membrane through α-DG is not essential for integrity of the basement membrane but is essential for stabilizing the plasma membrane against normal mechanical activity of myocardial cells.
MATERIALS AND METHODS
Mice
Homozygous mutant Largemyd mice as well as heterozygous and homozygous WT littermates were generated from mating heterozygous mice in a colony of B6C3Fe-a/a-LARGEmyd originally purchased from Jackson Laboratories. For our experiments, we used male and female age-matched littermate animals. Genotyping was performed using previously published primers (9). The procedures used in this study were approved by the University of Michigan Committee on the Use and Care of Animals. Animal care was provided by the University of Michigan Unit for Laboratory Animal Medicine in accordance with National Research Council's Guide for the Care and Use of Laboratory Animals (57).
Antibodies
We used following primary antibodies: rabbit polyclonal L9393 pan-laminin (Sigma, St Louis, MO, USA), rat monoclonal anti-laminin α-2 chain (Alexis, San-Diego, CA, USA), monoclonal anti-β-DG (Vector Labs, Burlingame, CA, USA), monoclonal anti-glycosylated epitope of α-DG IIH6 (kind gift of K. P. Campbell, University of Iowa), monoclonal anti-integrin α7 (Sigma) and rabbit polyclonal anti-integrin β1 antibody (Chemicon Billerica, MA, USA). Secondary antibodies used for western blotting were conjugated to horseradish peroxidase (Jackson ImmunoResearch, West Grove, PA, USA). Secondary antibodies for immunofluorescent imaging were conjugated to Alexa-488 (Molecular Probes, Invitrogen, Grand Island, NY, USA), DyLightTM488 (Jackson ImmunoResearch) and Cy3 (Jackson ImmunoResearch).
Assessment of myocardial membrane damage
Mice were anesthetized i.p. with a mixture of 100 μg/g ketamine and 8 μg/g xylazine. Hearts were quickly excised, weighed and snap frozen in liquid nitrogen cooled isopentane. Frozen hearts were sectioned in 8 μm thick slices in a cryostat and co-stained with antibodies against mouse IgG and pan-laminin. A goat anti-mouse IgG antibody conjugated to DyLightTM488 was from Jackson ImmunoResearch. Pan-laminin antibody (see above) was followed by secondary antibody conjugated to Cy3. We analyzed four serial sections at a 300 μm interval for each animal.
Cardiac myocyte primary culture
Adult cardiac myocytes were enzymatically isolated from 9 to 15 weeks old mice following a protocol we previously published (58). Plating and culture media contained 25 µm S-(−)-blebbistatin, a contraction inhibitor (Toronto Research Chemicals, North York, ON, Canada), unless otherwise stated (58). Cells were isolated from WT and Largemyd mice with 30–60 min interval and were treated similarly.
Quantification of cardiac myocytes adhesion
Cardiac myocytes were plated on glass cover slips placed in a 24-well plate in media supplemented with 30 mm of contraction inhibitor 2,3-butanedione monoximine (Sigma). Plating density was ∼350 cells/cm2 with a total of 400 cells/cover slip. The cover slips were coated with 50 and 1 µg/ml mouse laminin-111 (Invitrogen) and Dulbecco's phosphate buffered saline (PBS) as a control. Cells were left to attach for 30 min at 37°C in media containing no serum. The media were then changed to remove non-attached cells, and remaining cells were counted over the entire surface of a cover slip using ×4 objective of Olympus CKX31 inverted microscope (Olympus, Tokyo, Japan). Total of five to six cover slips were counted for each sample in each experiment.
Mechanical stretch in cardiac myocytes
Freshly isolated adult cardiac myocytes were plated on six-well plates containing silastic membranes (Flexcell, Hillsborough, NC, USA) coated with 50 µg/ml mouse laminin-111 for 30–40 min (Invitrogen). The plating density was ∼60 cells/mm2 with the total of 20 000 cells/well. Following 2 h of attachment, media were switched to media without serum and blebbistatin. The membrane impermeant dye, propidium iodide (Sigma), was added to final concentration of 50 µg/ml for 15 min before stretch. Cells were stretched for 1 h at 1 Hz using a custom-made cylinder-based pump and platform which replicated the platforms commercially available from Flexell International, to apply vacuum pressure to the bottom of a six-well dish with silastic membrane bottoms. The device was calibrated using a depth micrometer to measure the displacement of the membrane at the center, and an ellipse equation was used to calculate a stretch of the silastic membrane of 20%. After completion of stretch, cells were let rest for 30 min and then washed with media to remove extracellular propidium iodide. Cardiac myocytes were fixed in 3% paraformaldehyde for 15 min and washed three times with PBS. Silastic membranes were cut off the plates and mounted on glass slides with PermaFluor (Thermo Electron Corporation, Pittsburg, PA, USA). Cells were visualized using the red channel of an Olympus BX51 microscope (Olympus). Myocytes from WT and mutant mice were always isolated in pairs and tested in parallel wells under identical conditions with identical dye solutions. Digital images of five to six random fields of cells per sample were taken. The images were thresholded in parallel using Adobe Photoshop to eliminate background autofluorescence, and cells were then scored blindly for propidium iodide-positive nuclei above background, and cell morphology.
Immunofluorescent staining
Cells were plated on 22 mm square glass cover slips (Corning, NY, USA) coated with mouse collagen IV at a concentration of 50 ng/µl (Sigma). Cells were collected immediately after 2 h plating time or after 24–48 h in culture. Cells were fixed in 3% paraformaldehyde before subjecting to immunofluorescent staining. For heart tissue staining, hearts were collected as described above, and 8 μm cryosections were used.
Western blotting
Freshly isolated and cultured cells were washed with PBS and lysed in buffer containing 150 mm NaCl, 50 mm Tris pH 7.5, 1% Triton X-100, 1 mm EDTA and protease inhibitors (0.6 mm benzamidine, 0.4 mm PMSF, 0.5 μg/ml pepstatin, 2 kallikrein inhibitor units/ml aprotinin, 1 μg/ml leupeptin). Samples were sonicated for 10 s and centrifuged at 14 000 rpm for 5 min to pellet undissolved debris. Total protein content was determined using DC Protein Assay (Biorad, Hercules, CA, USA). Proteins were separated by a 3–15% gradient sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and then transferred to a polyvinylidene fluoridine membrane, which was stained with Ponceau S to verify equal loading. The membranes were blocked with 5% nonfat milk in TBS (100 mm Nacl, 50 mm Tris pH 7.5) and followed by incubation with primary and secondary antibodies (see above). The membranes were developed using an enhanced chemiluminiscence assay (Pierce, Rockford, IL, USA).
Microsome preparation
Snap frozen heart samples were homogenized in pyrophosphate buffer, pH 7.1, containing 1 mm MgCl, 0.303 m sucrose, 1 mm EDTA and protease inhibitors in concentrations indicated above. Homogenates were centrifuged at 14 000g at 4°C for 30 min, and supernatants were then centrifuged at 30 000g at 4°C for 30 min. Microsome pellets were washed twice with homogenization buffer and resuspended in 20 mm Tris, pH 7.0 containing 0.303 m sucrose. After quantification, microsomes were separated on SDS–PAGE and western blotted as described above.
Statistics
Student's t-test or one-way analysis of variance with Newman–Keuls post-test was performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA). A P-value <0.05 was considered significant. Values are expressed as mean ± SEM unless otherwise stated.
SUPPLEMENTARY MATERIAL
FUNDING
This work was supported by grants from National Institutes of Health (grant HL-080388 to D.E.M.) and an American Heart Association Postdoctoral Fellowship (0825876G to Z.K.).
Supplementary Material
ACKNOWLEDGEMENTS
We thank Abbie Renoux, Manali Rathod and Waseem Ahmed for technical assistance.
Conflict of Interest statement. None declared.
REFERENCES
- 1.Kirchmann C., Kececioglu D., Korinthenberg R., Dittrich S. Echocardiographic and electrocardiographic findings of cardiomyopathy in Duchenne and Becker-Kiener muscular dystrophies. Pediatr. Cardiol. 2005;26:66–72. doi: 10.1007/s00246-004-0689-2. doi:10.1007/s00246-004-0689-2. [DOI] [PubMed] [Google Scholar]
- 2.Saito M., Kawai H., Akaike M., Adachi K., Nishida Y., Saito S. Cardiac dysfunction with Becker muscular dystrophy. Am. Heart J. 1996;132:642–647. doi: 10.1016/s0002-8703(96)90250-1. doi:10.1016/S0002-8703(96)90250-1. [DOI] [PubMed] [Google Scholar]
- 3.Tsubata S., Bowles K.R., Vatta M., Zintz C., Titus J., Muhonen L., Bowles N.E., Towbin J.A. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J. Clin. Invest. 2000;106:655–662. doi: 10.1172/JCI9224. doi:10.1172/JCI9224. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Nakanishi T., Sakauchi M., Kaneda Y., Tomimatsu H., Saito K., Nakazawa M., Osawa M. Cardiac involvement in Fukuyama-type congenital muscular dystrophy. Pediatrics. 2006;117:e1187–e1192. doi: 10.1542/peds.2005-2469. doi:10.1542/peds.2005-2469. [DOI] [PubMed] [Google Scholar]
- 5.Michele D.E., Barresi R., Kanagawa M., Saito F., Cohn R.D., Satz J.S., Dollar J., Nishino I., Kelley R.I., Somer H., et al. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature. 2002;418:417–422. doi: 10.1038/nature00837. doi:10.1038/nature00837. [DOI] [PubMed] [Google Scholar]
- 6.Gene table of monogenic neuromuscular disorders (nuclear genome only) Neuromuscul. Disord. 2008;18:101–129. doi:10.1016/j.nmd.2007.12.001. [PubMed] [Google Scholar]
- 7.Barresi R., Michele D.E., Kanagawa M., Harper H.A., Dovico S.A., Satz J.S., Moore S.A., Zhang W., Schachter H., Dumanski J.P., et al. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat. Med. 2004;10:696–703. doi: 10.1038/nm1059. doi:10.1038/nm1059. [DOI] [PubMed] [Google Scholar]
- 8.Kanagawa M., Saito F., Kunz S., Yoshida-Moriguchi T., Barresi R., Kobayashi Y.M., Muschler J., Dumanski J.P., Michele D.E., Oldstone M.B., et al. Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell. 2004;117:953–964. doi: 10.1016/j.cell.2004.06.003. doi:10.1016/j.cell.2004.06.003. [DOI] [PubMed] [Google Scholar]
- 9.Grewal P.K., Holzfeind P.J., Bittner R.E., Hewitt J.E. Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse. Nat. Genet. 2001;28:151–154. doi: 10.1038/88865. doi:10.1038/88865. [DOI] [PubMed] [Google Scholar]
- 10.Grewal P.K., McLaughlan J.M., Moore C.J., Browning C.A., Hewitt J.E. Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies. Glycobiology. 2005;15:912–923. doi: 10.1093/glycob/cwi094. doi:10.1093/glycob/cwi094. [DOI] [PubMed] [Google Scholar]
- 11.Longman C., Brockington M., Torelli S., Jimenez-Mallebrera C., Kennedy C., Khalil N., Feng L., Saran R.K., Voit T., Merlini L., et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum. Mol. Genet. 2003;12:2853–2861. doi: 10.1093/hmg/ddg307. doi:10.1093/hmg/ddg307. [DOI] [PubMed] [Google Scholar]
- 12.Holzfeind P.J., Grewal P.K., Reitsamer H.A., Kechvar J., Lassmann H., Hoeger H., Hewitt J.E., Bittner R.E. Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Large(myd) mouse defines a natural model for glycosylation-deficient muscle–eye–brain disorders. Hum. Mol. Genet. 2002;11:2673–2687. doi: 10.1093/hmg/11.21.2673. doi:10.1093/hmg/11.21.2673. [DOI] [PubMed] [Google Scholar]
- 13.Hara Y., Balci-Hayta B., Yoshida-Moriguchi T., Kanagawa M., Beltran-Valero de Bernabe D., Gundesli H., Willer T., Satz J.S., Crawford R.W., Burden S.J., et al. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N. Engl. J. Med. 2011;364:939–946. doi: 10.1056/NEJMoa1006939. doi:10.1056/NEJMoa1006939. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Ervasti J.M., Campbell K.P. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 1993;122:809–823. doi: 10.1083/jcb.122.4.809. doi:10.1083/jcb.122.4.809. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Ibraghimov-Beskrovnaya O., Ervasti J.M., Leveille C.J., Slaughter C.A., Sernett S.W., Campbell K.P. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature. 1992;355:696–702. doi: 10.1038/355696a0. doi:10.1038/355696a0. [DOI] [PubMed] [Google Scholar]
- 16.Sugita S., Saito F., Tang J., Satz J., Campbell K., Sudhof T.C. A stoichiometric complex of neurexins and dystroglycan in brain. J. Cell Biol. 2001;154:435–445. doi: 10.1083/jcb.200105003. doi:10.1083/jcb.200105003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Gee S.H., Montanaro F., Lindenbaum M.H., Carbonetto S. Dystroglycan-alpha, a dystrophin-associated glycoprotein, is a functional agrin receptor. Cell. 1994;77:675–686. doi: 10.1016/0092-8674(94)90052-3. doi:10.1016/0092-8674(94)90052-3. [DOI] [PubMed] [Google Scholar]
- 18.Michele D.E., Kabaeva Z., Davis S.L., Weiss R.M., Campbell K.P. Dystroglycan matrix receptor function in cardiac myocytes is important for limiting activity-induced myocardial damage. Circ. Res. 2009;105:984–993. doi: 10.1161/CIRCRESAHA.109.199489. doi:10.1161/CIRCRESAHA.109.199489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Ervasti J.M., Ohlendieck K., Kahl S.D., Gaver M.G., Campbell K.P. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature. 1990;345:315–319. doi: 10.1038/345315a0. doi:10.1038/345315a0. [DOI] [PubMed] [Google Scholar]
- 20.Durbeej M., Cohn R.D., Hrstka R.F., Moore S.A., Allamand V., Davidson B.L., Williamson R.A., Campbell K.P. Disruption of the beta-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E. Mol. Cell. 2000;5:141–151. doi: 10.1016/s1097-2765(00)80410-4. doi:10.1016/S1097-2765(00)80410-4. [DOI] [PubMed] [Google Scholar]
- 21.Matsumura K., Chiba A., Yamada H., Fukuta-Ohi H., Fujita S., Endo T., Kobata A., Anderson L.V., Kanazawa I., Campbell K.P., et al. A role of dystroglycan in schwannoma cell adhesion to laminin. J. Biol. Chem. 1997;272:13904–13910. doi: 10.1074/jbc.272.21.13904. doi:10.1074/jbc.272.21.13904. [DOI] [PubMed] [Google Scholar]
- 22.de Bernabe D.B., Inamori K., Yoshida-Moriguchi T., Weydert C.J., Harper H.A., Willer T., Henry M.D., Campbell K.P. Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE. J. Biol. Chem. 2009;284:11279–11284. doi: 10.1074/jbc.C900007200. doi:10.1074/jbc.C900007200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Sgambato A., Migaldi M., Montanari M., Camerini A., Brancaccio A., Rossi G., Cangiano R., Losasso C., Capelli G., Trentini G.P., et al. Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am. J. Pathol. 2003;162:849–860. doi: 10.1016/S0002-9440(10)63881-3. doi:10.1016/S0002-9440(10)63881-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Colognato H., Winkelmann D.A., Yurchenco P.D. Laminin polymerization induces a receptor-cytoskeleton network. J. Cell Biol. 1999;145:619–631. doi: 10.1083/jcb.145.3.619. doi:10.1083/jcb.145.3.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.McKee K.K., Harrison D., Capizzi S., Yurchenco P.D. Role of laminin terminal globular domains in basement membrane assembly. J. Biol. Chem. 2007;282:21437–21447. doi: 10.1074/jbc.M702963200. doi:10.1074/jbc.M702963200. [DOI] [PubMed] [Google Scholar]
- 26.Henry M.D., Campbell K.P. A role for dystroglycan in basement membrane assembly. Cell. 1998;95:859–870. doi: 10.1016/s0092-8674(00)81708-0. doi:10.1016/S0092-8674(00)81708-0. [DOI] [PubMed] [Google Scholar]
- 27.Williamson R.A., Henry M.D., Daniels K.J., Hrstka R.F., Lee J.C., Sunada Y., Ibraghimov-Beskrovnaya O., Campbell K.P. Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum. Mol. Genet. 1997;6:831–841. doi: 10.1093/hmg/6.6.831. doi:10.1093/hmg/6.6.831. [DOI] [PubMed] [Google Scholar]
- 28.Poppe M., Cree L., Bourke J., Eagle M., Anderson L.V., Birchall D., Brockington M., Buddles M., Busby M., Muntoni F., et al. The phenotype of limb-girdle muscular dystrophy type 2I. Neurology. 2003;60:1246–1251. doi: 10.1212/01.wnl.0000058902.88181.3d. [DOI] [PubMed] [Google Scholar]
- 29.Poppe M., Bourke J., Eagle M., Frosk P., Wrogemann K., Greenberg C., Muntoni F., Voit T., Straub V., Hilton-Jones D., et al. Cardiac and respiratory failure in limb-girdle muscular dystrophy 2I. Ann. Neurol. 2004;56:738–741. doi: 10.1002/ana.20283. doi:10.1002/ana.20283. [DOI] [PubMed] [Google Scholar]
- 30.Boito C.A., Melacini P., Vianello A., Prandini P., Gavassini B.F., Bagattin A., Siciliano G., Angelini C., Pegoraro E. Clinical and molecular characterization of patients with limb-girdle muscular dystrophy type 2I. Arch. Neurol. 2005;62:1894–1899. doi: 10.1001/archneur.62.12.1894. doi:10.1001/archneur.62.12.1894. [DOI] [PubMed] [Google Scholar]
- 31.Brockington M., Blake D.J., Prandini P., Brown S.C., Torelli S., Benson M.A., Ponting C.P., Estournet B., Romero N.B., Mercuri E., et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am. J. Hum. Genet. 2001;69:1198–1209. doi: 10.1086/324412. doi:10.1086/324412. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Brockington M., Yuva Y., Prandini P., Brown S.C., Torelli S., Benson M.A., Herrmann R., Anderson L.V., Bashir R., Burgunder J.M., et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum. Mol. Genet. 2001;10:2851–2859. doi: 10.1093/hmg/10.25.2851. doi:10.1093/hmg/10.25.2851. [DOI] [PubMed] [Google Scholar]
- 33.Wahbi K., Meune C., Hamouda el H., Stojkovic T., Laforet P., Becane H.M., Eymard B., Duboc D. Cardiac assessment of limb-girdle muscular dystrophy 2I patients: an echography, Holter ECG and magnetic resonance imaging study. Neuromuscul. Disord. 2008;18:650–655. doi: 10.1016/j.nmd.2008.06.365. doi:10.1016/j.nmd.2008.06.365. [DOI] [PubMed] [Google Scholar]
- 34.D'Amico A., Petrini S., Parisi F., Tessa A., Francalanci P., Grutter G., Santorelli F.M., Bertini E. Heart transplantation in a child with LGMD2I presenting as isolated dilated cardiomyopathy. Neuromuscul. Disord. 2008;18:153–155. doi: 10.1016/j.nmd.2007.09.013. doi:10.1016/j.nmd.2007.09.013. [DOI] [PubMed] [Google Scholar]
- 35.Murakami T., Hayashi Y.K., Noguchi S., Ogawa M., Nonaka I., Tanabe Y., Ogino M., Takada F., Eriguchi M., Kotooka N., et al. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann. Neurol. 2006;60:597–602. doi: 10.1002/ana.20973. doi:10.1002/ana.20973. [DOI] [PubMed] [Google Scholar]
- 36.Wooddell C.I., Zhang G., Griffin J.B., Hegge J.O., Huss T., Wolff J.A. Use of Evans blue dye to compare limb muscles in exercised young and old mdx mice. Muscle Nerve. 2010;41:487–499. doi: 10.1002/mus.21527. doi:10.1002/mus.21527. [DOI] [PubMed] [Google Scholar]
- 37.Li S., Harrison D., Carbonetto S., Fassler R., Smyth N., Edgar D., Yurchenco P.D. Matrix assembly, regulation, and survival functions of laminin and its receptors in embryonic stem cell differentiation. J. Cell Biol. 2002;157:1279–1290. doi: 10.1083/jcb.200203073. doi:10.1083/jcb.200203073. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Petrof B.J., Shrager J.B., Stedman H.H., Kelly A.M., Sweeney H.L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl Acad. Sci. USA. 1993;90:3710–3714. doi: 10.1073/pnas.90.8.3710. doi:10.1073/pnas.90.8.3710. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Boutonnat J., Barbier M., Muirhead K., Mousseau M., Ronot X., Seigneurin D. Optimized fluorescent probe combinations for evaluation of proliferation and necrosis in anthracycline-treated leukaemic cell lines. Cell Prolif. 1999;32:203–213. doi: 10.1046/j.1365-2184.1999.3240203.x. doi:10.1046/j.1365-2184.1999.3240203.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Lundgren E., Terracio L., Borg T.K. Adhesion of cardiac myocytes to extracellular matrix components. Basic Res. Cardiol. 1985;80(Suppl. 1)):69–74. doi: 10.1007/978-3-662-11041-6_13. [DOI] [PubMed] [Google Scholar]
- 41.Yurchenco P.D., Patton B.L. Developmental and pathogenic mechanisms of basement membrane assembly. Curr. Pharm. Des. 2009;15:1277–1294. doi: 10.2174/138161209787846766. doi:10.2174/138161209787846766. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Boppart M.D., Burkin D.J., Kaufman S.J. Alpha7beta1-integrin regulates mechanotransduction and prevents skeletal muscle injury. Am. J. Physiol. Cell Physiol. 2006;290:C1660–C1665. doi: 10.1152/ajpcell.00317.2005. doi:10.1152/ajpcell.00317.2005. [DOI] [PubMed] [Google Scholar]
- 43.Burkin D.J., Wallace G.Q., Nicol K.J., Kaufman D.J., Kaufman S.J. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J. Cell Biol. 2001;152:1207–1218. doi: 10.1083/jcb.152.6.1207. doi:10.1083/jcb.152.6.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Yang W., Lin Q., Guan J.L., Cerione R.A. Activation of the Cdc42-associated tyrosine kinase-2 (ACK-2) by cell adhesion via integrin beta1. J. Biol. Chem. 1999;274:8524–8530. doi: 10.1074/jbc.274.13.8524. doi:10.1074/jbc.274.13.8524. [DOI] [PubMed] [Google Scholar]
- 45.Sanes J.R. The basement membrane/basal lamina of skeletal muscle. J. Biol. Chem. 2003;278:12601–12604. doi: 10.1074/jbc.R200027200. doi:10.1074/jbc.R200027200. [DOI] [PubMed] [Google Scholar]
- 46.Hayashi Y.K., Engvall E., Arikawa-Hirasawa E., Goto K., Koga R., Nonaka I., Sugita H., Arahata K. Abnormal localization of laminin subunits in muscular dystrophies. J. Neurol. Sci. 1993;119:53–64. doi: 10.1016/0022-510x(93)90191-z. doi:10.1016/0022-510X(93)90191-Z. [DOI] [PubMed] [Google Scholar]
- 47.Rybakova I.N., Patel J.R., Ervasti J.M. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J. Cell Biol. 2000;150:1209–1214. doi: 10.1083/jcb.150.5.1209. doi:10.1083/jcb.150.5.1209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Ervasti J.M. Costameres: the Achilles' heel of Herculean muscle. J. Biol. Chem. 2003;278:13591–13594. doi: 10.1074/jbc.R200021200. doi:10.1074/jbc.R200021200. [DOI] [PubMed] [Google Scholar]
- 49.Ramaswamy K.S., Palmer M.L., van der Meulen J.H., Renoux A., Kostrominova T.Y., Michele D.E., Faulkner J.A. Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats. J. Physiol. 2011;589:1195–1208. doi: 10.1113/jphysiol.2010.201921. doi:10.1113/jphysiol.2010.201921. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Straub V., Rafael J.A., Chamberlain J.S., Campbell K.P. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J. Cell Biol. 1997;139:375–385. doi: 10.1083/jcb.139.2.375. doi:10.1083/jcb.139.2.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Wehling M., Spencer M.J., Tidball J.G. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J. Cell Biol. 2001;155:123–131. doi: 10.1083/jcb.200105110. doi:10.1083/jcb.200105110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Mariol M.C., Segalat L. Muscular degeneration in the absence of dystrophin is a calcium-dependent process. Curr. Biol. 2001;11:1691–1694. doi: 10.1016/s0960-9822(01)00528-0. doi:10.1016/S0960-9822(01)00528-0. [DOI] [PubMed] [Google Scholar]
- 53.Coral-Vazquez R., Cohn R.D., Moore S.A., Hill J.A., Weiss R.M., Davisson R.L., Straub V., Barresi R., Bansal D., Hrstka R.F., et al. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell. 1999;98:465–474. doi: 10.1016/s0092-8674(00)81975-3. doi:10.1016/S0092-8674(00)81975-3. [DOI] [PubMed] [Google Scholar]
- 54.Yasuda S., Townsend D., Michele D.E., Favre E.G., Day S.M., Metzger J.M. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature. 2005;436:1025–1029. doi: 10.1038/nature03844. doi:10.1038/nature03844. [DOI] [PubMed] [Google Scholar]
- 55.Villalta S.A., Rinaldi C., Deng B., Liu G., Fedor B., Tidball J.G. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum. Mol. Genet. 2011;20:790–805. doi: 10.1093/hmg/ddq523. doi:10.1093/hmg/ddq523. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Spurney C.F., Sali A., Guerron A.D., Iantorno M., Yu Q., Gordish-Dressman H., Rayavarapu S., van der Meulen J., Hoffman E.P., Nagaraju K. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J. Cardiovasc. Pharmacol. Ther. 2011;16:87–95. doi: 10.1177/1074248410381757. doi:10.1177/1074248410381757. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Institute for Laboratory Animal Research. National Research Council. Washington, DC: Guide for the care and use of laboratory animals. National Academy Press; 1996. [Google Scholar]
- 58.Kabaeva Z., Zhao M., Michele D.E. Blebbistatin extends culture life of adult mouse cardiac myocytes and allows efficient and stable transgene expression. Am. J. Physiol. Heart Circ. Physiol. 2008;294:H1667–H1674. doi: 10.1152/ajpheart.01144.2007. doi:10.1152/ajpheart.01144.2007. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.






